Tin tức & Cập nhật
Xem bài viết Bệnh nhiễm khuẩn
Xem
Chỉ hiển thị Multimedia

Switch to B/F/TAF maintains viral suppression in people with HIV-1, HBV
20 Mar 2025
bởiStephen Padilla
Following the switch from dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF), treatment with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) has shown efficacy in keeping HIV-1 and hepatitis B virus (HBV) at low levels in the blood through 48 weeks of the open-label extension (OLE) phase of the ALLIANCE study.
20 Mar 2025








